Key Takeaways
- Profitability restored, diversification drove it: Net profit swung from a ₹6.13 crore loss to a ₹4.21 crore gain YoY, powered by a ~900 bps contribution margin jump as Saudi Arabia and Africa displaced weak UAE volumes.
- Order book holds at ₹900+ crore despite slippage: Geopolitical uncertainty pushed several large-ticket orders into later quarters, but none were cancelled; the outstanding book, conservatively stated, still provides roughly two-year visibility.
- Two acquisitions on track, one already winning work: The Saudi civil entity (SACE) closed its first order within days of the deal; due diligence on the European target is progressing, with both expected to close this financial year.
- Full-year 20–25% organic growth guide reaffirmed: Management explicitly tied its confidence to the H2-weighted nature of the business, not to any Q1 recovery signal, and flagged Q2 as merely steady.
- What to watch next quarter: Whether the slipped orders actually convert, the pace of Saudi receivable collection on the ~₹120 crore contract, and any concrete update on the European acquisition structure.
Profitability & Margin Structure
- Contribution margin leap: Expanded ~900 bps YoY to 46.7%, driven by a geographical mix shift toward Saudi Arabia and North Africa, better project execution quality, scope mix, and procurement efficiency.
- Cost of goods sold fell despite revenue growth: COGS declined 3.35% YoY to ₹41.62 crore even as topline grew 10%, a direct result of the mix shift toward higher-value markets.
- Finance costs dropped sharply: Fell 36% YoY to ₹0.86 crore, reflecting more efficient use of working capital and external borrowing enabled by strategic deployment of IPO proceeds.
- Employee cost leverage: Restructuring and localization reduced employee costs, giving operating leverage that already kicked in during the lightest quarter of the year.
- Further margin levers identified: Management is evaluating procurement from countries like China, where customers are comfortable, to expand gross margin, while controlling fixed costs so operating leverage accelerates as the top line grows.
- PAT guidance set: Management guided 9 to 11% PAT alongside roughly 25% growth.
Aman Anavkar: "We cannot give you shareholder value like the unicorns of the industry, which are loss making and still shareholder value is going up. We are a genuine business which is profitable, which is growing, which is actually delivering substance in the right markets."
Revenue & Order Book Dynamics
- 10% YoY revenue growth, carried by new geographies: Saudi Arabia grew 130% YoY to ₹17.14 crore, while new markets Morocco and Kenya together contributed ₹27.94 crore, more than offsetting severe regional headwinds in the UAE FTS segment.
- Order inflows hit by geopolitics, not demand destruction: ₹96.5 crore of orders were added in Q1, but several predictably larger orders expected to finalize were pushed to subsequent quarters due to geopolitical conditions and donor or government funding cycles; no cancellations, client teams remain engaged.
- Order book conservatively stated at ₹900+ crore: Exchange rate fluctuations mean the book should ideally be ₹920+ crore, but management quotes the lower figure; the book and pipeline together provide roughly two-year visibility.
- Revenue recognition is structurally H2-weighted: Recognition follows engineering milestones, site readiness, and customer approvals, all of which cluster in Q3 and Q4; Q1 is the lightest quarter by design, so it signals execution quality rather than full-year momentum.
- Receivables elevated but secured: Trade receivables rose slightly to ~₹215 crore despite the return to profitability; most are backed by LCs or CAD, and the aging credit is mainly retention money with 1–2 year periods representing 10–15% of delivery value.
- Saudi receivable tied to project completion: A large ~₹120 crore contract has goods shipped and invoices raised, but the receivable is stuck until installation and delivery of the entire project completes; advances already received but not knocked off; delivery expected by Q3.
- Repeat customer share deliberately lower: Repeat customers were ~10% of revenue this quarter, down from prior years, because management actively chose to diversify and pursue new projects that will become repeat customers later.
Ashwani Singh: "This seasonality is a feature of our order execution cycle, not a signal of momentum, and it is precisely why we remain confident of meeting our full year guidance of 20% to 25% organic growth."
Geographic Diversification & Resilience
- UAE weakness absorbed without derailing the group: The UAE FTS segment faced genuine regional headwinds from the Middle East war; the diversification built over the past twelve months allowed one region's weakness to be absorbed without hurting group performance.
- Saudi Arabia is now a local platform, not an export destination: The incorporation of Specialized Contracting Activities LLC, with Fabtech holding 51%, gives a licensed local platform to pursue MEP and civil infrastructure projects; the acquired SACE entity already won one civil order within ten days of the call.
- Africa pipeline building beyond the Botswana win: A ₹31.23 crore veterinary vaccine manufacturing facility was secured in Botswana during the quarter; three more vaccine projects are under negotiation in Africa, and a Djibouti project for IV solutions, dialysis products, and water for injection was recently finalized with government funding.
- PEB bidding book at ~₹400 crore: Bids for pre-engineered buildings scope in Africa and the Middle East have grown over the last two quarters; management is hoping for positive outcomes.
- UAE normalization timeline is unknowable: Management tied any forecast to geopolitical resolution, stating plainly that it cannot answer until the US president's stance is clear, though it hopes normalization happens fast.
- Competitive advantage is local incumbency with references: Fabtech built the first and largest US FDA-approved plants in the Middle East, the largest IV solution plants in the region, and the first biosimilar oncology plant in northern Africa; it competes with European firms, not Indian or Chinese ones, on cost, execution speed, integrated process and water capability, and customer relationships.
Aman Anavkar: "We're not going to dress that up, but what the quarter demonstrates is that the diversification that we have built now has built. One region's weakness to be absorbed without derailing the group performance. That resilience is the point of our strategy."
Inorganic Growth & IPO Proceeds Deployment
- Saudi acquisition (SACE) is live and winning: The first IPO-proceeds inorganic move acquired a majority stake in Specialized Activities Contracting Establishment, making Fabtech a local entity that can bid for pharmaceutical and non-pharmaceutical HVAC, MEP, and civil projects; one civil order was finalized shortly after announcement.
- European acquisition in due diligence: The second IPO-proceeds opportunity is progressing through business due diligence with detailed integration strategies in place; management is taking time to ensure the right strategic fit and correct structure, describing the caution as "it is better to know who you're getting married to."
- Both acquisitions expected this financial year: Subject to customary approvals and closing conditions, both the Italian and Saudi Arabian acquisitions are on track to complete before the end of the current financial year.
- Investment approvals in place: The board approved an investment of up to ₹24 crore into Fabtech Technologies LLC, along with additional investment into FT Institutions Private Limited.
Aman Anavkar: "That is what moves us from being a vendor to being a partner. It is also what protects contribution margin, because early engagement is where specifications get shaped."
Accounting, Working Capital & Financial Management
- Shift to percentage-of-completion method being evaluated: Management is consulting auditors on moving from milestone-based or shipment-based accounting to percentage-of-completion; new contracts are being reworked accordingly, but existing contracts remain on the old basis, so the change is expected "in the next few years."
- Monthly revenue recognition is a multi-year goal: Management is trying to renegotiate customer contracts to start revenue recognition on a monthly basis rather than on shipment, but that transition is a couple of years away and depends on contract changes.
- Working capital cycle stable at ~120 days: The company holds ~₹110 crore in advances from customers; ~₹20–22 crore of goods were stuck at port at quarter-end due to shipment unavailability, but working capital was not materially impacted.
- Working capital benefit expected to persist: Management expects the benefit of the optimized working capital cycle to continue flowing through in coming quarters.
Strategy & Long-Term Vision
- Organic ₹1,000 crore-plus topline target by 2030: Management described this as a "bit conservative approach" per internal communication, covering organic growth only.
- Vision 2030 / 2035 document in progress: Management is working on a formal vision document to share with investors, alongside new IR, PR, and media coverage strategies whose effect is expected in the next quarter.
- Growth priorities are localization, pipeline discipline, and acquisition integration: The three stated priorities are deepening localization by investing further in international subsidiaries, converting the hot lead pipeline with contribution margin as the governing metric, and integrating incoming acquisitions to add genuine local execution capability.
- Management acknowledges the stock price disconnect: Leadership noted the pain of seeing the stock below the IPO price and invited guidance from the investor community on what else would help the share price reflect company performance, while emphasizing the business is growing conventionally, profitably, and as committed.
- Institutional engagement roadmap noted: Management acknowledged advice to engage first with family offices, AIFs, and PMS at the current market cap, then with micro-cap and small-cap mutual funds and institutional investors once crossing ₹1,000 crore market cap, calling the point "well taken."
Aman Anavkar: "I don't know if there's anything more important than life, right? And that is where and why we call ourselves life engineers."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic revenue growth | 20% to 25% year-on-year | Full year FY27 |
| PAT margin | 9% to 11% | Full year FY27 |
| Saudi and European acquisitions | Both to close, subject to approvals and conditions | Before end of FY27 |
| Saudi ~₹120 crore contract delivery | Full delivery and collections to begin as shipments complete | By Q3 FY27 |
| Organic topline target | ₹1,000 crore plus, organic only | By 2030 |
| Accounting method change | Shift from milestone/shipment-based to percentage-of-completion for new contracts | "Next few years" |
| European acquisition close | Due diligence and structuring to complete | "Next two to three quarters" |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Consolidated revenue | ₹74.98 cr, +10% YoY over ₹68.01 cr in Q1 FY26 |
| Consolidated net profit | ₹4.21 cr, versus net loss of ₹6.13 cr in Q1 FY26 |
| EBITDA | ₹7.41 cr, margin 9%, versus negative EBITDA of ₹5.27 cr in Q1 FY26 |
| Contribution margin | 46.7%, expanded 910 bps YoY from 37.6% |
| Cost of goods sold | ₹41.62 cr, declined 3.35% YoY |
| Finance cost | ₹0.86 cr, fell 36% YoY from ₹1.34 cr |
| Full-year organic growth guidance | 20–25% YoY, management remains confident |
| PAT guidance | 9–11%, with growth of around 25%; management targeting higher |
| Organic top-line target by 2030 | ₹1,000 cr plus |
| Open order book | Over ₹900 cr as of June 30, 2026; ideally ₹920+ cr |
| New order inflows | ₹96.5 cr added in Q1 FY27 |
| Active inquiries | Exceeding ₹9,300 cr |
| Hot leads | Over ₹3,800 cr, opportunities at advanced commercial or technical stages |
| Saudi Arabia revenue | ₹17.14 cr, +130% YoY |
| Morocco and Kenya combined revenue | ₹27.94 cr, markets not material a year ago |
| Trade receivables | ~₹215 cr, up from ₹211 cr at March end; customer advances at ₹110 cr |
| Repeat customer revenue share | ~10% of Q1 revenue |